LENZ THERAPEUTICS INC SEC Filings

Amendment No. 7 to a Schedule 13D reports ownership and recent sales of LENZ Therapeutics, Inc. common stock by multiple Versant-related entities. The filing lists Versant Venture Capital VI, L.P. (Versant VI) as holding 1,400,220 shares, representing 4.9% of the outstanding shares (based on 28,522,096 shares reported as of July 24, 2025). Versant Vantage II, L.P. holds 842,162 shares (3.0%). Versant Venture Capital VII, L.P. holds 1,033,412 shares (including a warrant for 70,534 shares), representing 3.6% on an adjusted basis.

The Amendment discloses share sales: on August 15, 2025 Versant VI sold 145,051 shares at $39.50 per share (proceeds ~$5,729,514.50) and Versant VII sold 69,949 shares at $39.50 (proceeds ~$2,762,985.50). On August 18, 2025 Versant VI sold 30,628 shares at a weighted average $38.5611 (proceeds ~$1,181,049.37) and Versant VII sold 15,085 shares at the same weighted average (proceeds ~$581,694.19). The Amendment updates cover-page holdings and clarifies related general partner relationships; other items from the original Schedule 13D remain unchanged.

Versant-affiliated investment vehicles reported multiple sales of LENZ Therapeutics common stock in mid-August 2025. Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P. sold a total of 260,713 shares across transactions dated 08/15/2025 and 08/18/2025 at prices ranging from $38.26 to $39.50 (a weighted average price reported for some sales as $38.5611). After the reported disposals, the filing shows Versant Venture Capital VI beneficially owned 1,430,848 shares (direct) and 977,963 shares (indirect) in related accounts; Versant Vantage II and affiliated entities reported 842,162 shares (indirect). The filing includes customary disclosure of the general partner/GP-GP structure and disclaimers of beneficial ownership except for pecuniary interests.

LENZ Therapeutics, Inc. (LENZ) – Form 4 insider transaction filed 07/01/2025

Versant Venture Capital VI, L.P. (together with affiliated Versant entities, a >10% beneficial owner of LENZ) reported the sale of 200,000 LENZ common shares on 06/27/2025 at a weighted-average price of $30.465 per share (price range $30.18–$30.75). Following the disposition, the filing shows:

• Direct ownership by Versant Venture Capital VI of 1,767,275 shares.
• Indirect ownership of 1,047,912 shares through Versant Venture Capital VII, L.P. (footnote 3).
• Indirect ownership of 842,162 shares through Versant Vantage II, L.P. (footnote 4).

The aggregate direct sale represents roughly 10.2% of Versant VI’s reported direct holdings before the transaction (calculation assumes no other changes) and signals the first disclosed disposition by the Versant funds in 2025. No derivative security activity was reported. The entities remain above the 10% ownership threshold and continue to have board representation.

Amendment No. 5 to Schedule 13D discloses the current ownership position of several Versant-affiliated investment vehicles in LENZ Therapeutics, Inc. ("LENZ") common stock.

The filing, dated 20 June 2025, lists six related reporting persons:

• Versant Venture Capital VI, L.P. ("Versant VI")
• Versant Ventures VI GP, L.P.
• Versant Ventures VI GP-GP, LLC
• Versant Vantage II, L.P. ("Vantage II")
• Versant Vantage II GP, L.P.
• Versant Vantage II GP-GP, LLC

Key beneficial ownership details are as follows:

• Versant VI: 1,967,275 shares with 7.0 % of outstanding common stock. The fund holds sole voting and dispositive power over the shares.
• Vantage II: 842,162 shares with 3.0 % of outstanding common stock. The fund also exercises sole voting and dispositive power.

Collectively, the two primary funds report 2,809,437 shares, equating to roughly 10 % of LENZ’s 28,146,154 shares outstanding (per the company’s Form 10-Q filed 7 May 2025). Control of the shares flows through the respective general partners and managing entities, which are therefore shown with shared voting and dispositive powers.

No financing source other than working capital ("WC") for the limited partnerships and affiliate funds ("AF") for the GP entities is cited, and the amendment does not disclose any legal proceedings. The filing provides no narrative on investment intent, purchase or sale transactions, or future plans; it simply updates ownership percentages and capital structure references.

For investors, the disclosure confirms that Versant remains a significant, though non-controlling, strategic shareholder in LENZ. There are no explicit signals of activist activity or immediate liquidity events contained in this amendment.